CRTX News and Press, Cortexyme Inc. From 02/01/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short-squeeze stocks continue to be hot with traders and we’re going over five candidates that investors will want to watch today. Source: Alextype/Shutterstock.com Today’s list of short-squeeze candid...

Cortexyme (NASDAQ:CRTX) provided a business update and announced key milestones for 2022. COR588 in mild to moderate Alzheimer’s Disease (AD): COR588 is currently completing a Phase 1 SAD/MAD trial in a cohort of healthy participants in Australia with study results expected in Q2 2022....

Next generation lysine gingipain inhibitor COR588 with novel structure and improved pharmacologic and safety profile prioritized for Alzheimer’s development Additional pipeline includes therapeutics in development for coronavirus infection, periodontal disease, and prev...

Christopher Lowe appointed interim chief executive officer David Lamond named chairman of the board Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced that its boar...

More bad news for Cortexyme (NASDAQ: CRTX) shareholders -- with its stock already down more than 90% from August's peak, as of 1:11 p.m. ET Wednesday, the stock's lost 30.1% of yesterday's closing price. Today's setback is in response to the company's announcement that the U.S. Food...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced that the company received a letter from the U.S. Food and Drug Administration (FDA) on January 25, 2022 placing a full clinical hold ...

Shares of the central nervous system drug specialist Cortexyme (NASDAQ: CRTX) plummeted by a hefty 54% over the course of 2021, according to data provided by S&P Global Market Intelligence . The clinical-stage drugmaker 's shares imploded last year in response to the fai...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Has Wall Street gotten ahead of itself? Depending on where one looks, it’s a fair enough question these days. But that certainly doesn’t include the market’s most-shorted stocks. Let’s take a l...

Cortexyme (NASDAQ:CRTX) has struck an Open Market Sale Agreement with Jefferies to periodically issue and sell up to $150M of company common stock of par value $0.001 per share. The company has filed a prospectus supplement with the SEC in this regard, Cortexyme (CRTX) said in a regulatory fi...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...